Core Viewpoint - The stock of Dabo Medical (002901) has experienced a decline of 3.05% as of October 14, 2025, closing at 57.2 yuan, with significant net outflows from retail and speculative investors [1][2]. Financial Performance - Dabo Medical reported a main revenue of 1.21 billion yuan for the first half of 2025, representing a year-on-year increase of 25.55% [3] - The net profit attributable to shareholders was 244 million yuan, up 76.69% year-on-year [3] - The second quarter of 2025 saw a single-quarter main revenue of 660 million yuan, a 22.96% increase year-on-year [3] - The company achieved a gross margin of 71.01% and a net margin of 21.42% [3] Market Position - Dabo Medical's total market capitalization is 23.682 billion yuan, ranking 9th in the medical device industry [3] - The company has a price-to-earnings ratio of 48.48, which is lower than the industry average of 66.45 [3] - The return on equity (ROE) stands at 7.6%, significantly higher than the industry average of 1.8% [3] Capital Flow Analysis - On October 14, 2025, the net inflow of main funds was 8.5985 million yuan, accounting for 3.81% of the total transaction amount [1][2] - Over the past five days, the stock has seen fluctuations in capital flow, with notable net outflows from retail investors [2]

Core Insights - The stock of Dabo Medical (002901) closed at 58.18 yuan on October 9, 2025, with a rise of 3.89% and a trading volume of 64,900 hands, resulting in a transaction amount of 379 million yuan [1] Group 1: Financial Performance - Dabo Medical reported a main business revenue of 1.21 billion yuan for the first half of 2025, an increase of 25.55% year-on-year [3] - The net profit attributable to shareholders was 244 million yuan, up 76.69% year-on-year [3] - The second quarter of 2025 saw a single-quarter main business revenue of 660 million yuan, a year-on-year increase of 22.96% [3] - The company achieved a gross profit margin of 71.01% and a net profit margin of 21.42% [3] Group 2: Market Position - Dabo Medical's total market capitalization is 24.088 billion yuan, ranking 9th in the medical device industry [3] - The company has a price-to-earnings ratio (P/E) of 49.31, which is lower than the industry average of 67.16 [3] - The return on equity (ROE) stands at 7.6%, significantly higher than the industry average of 1.8% [3] Group 3: Capital Flow - On October 9, 2025, the net inflow of main funds was 22.5649 million yuan, accounting for 5.95% of the total transaction amount [2] - Retail investors experienced a net outflow of 30.9949 million yuan, representing 8.18% of the total transaction amount [2] - Over the past five days, the stock has seen fluctuations in capital flow, with varying net inflows and outflows from different investor categories [2]

证券日报网讯大博医疗10月9日在互动平台回答投资者提问时表示，公司2025年第三季度报告的预约披 露日为2025年10月29日。 （文章来源：证券日报） ...

大博医疗（002901.SZ）10月9日在投资者互动平台表示，公司2025年第三季度报告的预约披露日为2025 年10月29日。 （记者 王瀚黎） 每经AI快讯，有投资者在投资者互动平台提问：请问贵公司什么时候发布三季报？ ...

Group 1 - The core viewpoint of the news is that Dabo Medical's stock has increased by 5%, reaching a price of 58.80 CNY per share, with a trading volume of 204 million CNY and a turnover rate of 1.22%, resulting in a total market capitalization of 24.344 billion CNY [1] - Dabo Medical Technology Co., Ltd. is located in Xiamen, Fujian Province, established on August 12, 2004, and listed on September 22, 2017. The company specializes in the production, research, and sales of high-value medical consumables [1] - The main business revenue composition includes trauma products (38.68%), spinal products (17.95%), minimally invasive surgical products (16.34%), joint products (10.37%), other products (9.27%), neurosurgery products (4.50%), and dental products (2.89%) [1] Group 2 - From the perspective of Dabo Medical's top ten circulating shareholders, a fund under Southern Fund ranks among them. The Southern CSI 1000 ETF (512100) increased its holdings by 141,900 shares in the second quarter, holding a total of 756,800 shares, which accounts for 0.26% of the circulating shares [2] - The estimated floating profit for the Southern CSI 1000 ETF today is approximately 2.119 million CNY. The fund was established on September 29, 2016, with a latest scale of 64.953 billion CNY. Year-to-date returns are 28.58%, ranking 2093 out of 4221 in its category; the one-year return is 34.04%, ranking 1521 out of 3848; and the return since inception is 13.79% [2]

Group 1 - The core viewpoint of the news is that Dabo Medical has seen a stock price increase of 5.02%, reaching 56.11 CNY per share, with a total market capitalization of 23.231 billion CNY [1] - Dabo Medical, established on August 12, 2004, and listed on September 22, 2017, specializes in the production, research, and sales of high-value medical consumables [1] - The revenue composition of Dabo Medical includes trauma products (38.68%), spinal products (17.95%), minimally invasive surgical products (16.34%), joint products (10.37%), other products (9.27%), neurosurgical products (4.50%), and dental products (2.89%) [1] Group 2 - Southern Fund's Southern CSI 1000 ETF (512100) is among the top ten circulating shareholders of Dabo Medical, having increased its holdings by 141,900 shares in the second quarter, totaling 756,800 shares, which represents 0.26% of the circulating shares [2] - The Southern CSI 1000 ETF has achieved a year-to-date return of 27.27% and a one-year return of 47.41%, ranking 2099 out of 4220 and 1424 out of 3846 respectively [2] - The fund manager, Cui Lei, has been in charge for 6 years and 329 days, with the fund's total asset size at 94.976 billion CNY and a best return of 145.53% during the tenure [3]

Group 1 - The core viewpoint of the news is that Dabo Medical has seen a stock price increase of 5.09%, reaching 55.10 CNY per share, with a total market capitalization of 22.812 billion CNY [1] - Dabo Medical specializes in the production, research, and sales of high-value medical consumables, with its main revenue sources being trauma products (38.68%), spinal products (17.95%), minimally invasive surgical products (16.34%), joint products (10.37%), and others [1] Group 2 - From the perspective of fund holdings, one fund under Jiashi Fund has Dabo Medical as a top ten holding, with 204,000 shares held, accounting for 0.94% of the fund's net value [2] - Jiashi Research Selected Mixed Fund (070013) has achieved a year-to-date return of 11.47% and a one-year return of 25.29%, ranking 5506 out of 8173 and 5455 out of 7996 respectively [2] Group 3 - The fund manager of Jiashi Research Selected Mixed Fund is Chen Yong, who has been in position for 3 years and 117 days, and Xiao Mi, who has been in position for 8 years and 272 days [3] - The total asset size of Jiashi Research Selected Mixed Fund is 783 million CNY, while the total asset size of Xiao Mi's fund is 5.028 billion CNY [3]

Group 1 - The core viewpoint of the news is that Dabo Medical has seen a stock price increase of 5.09%, reaching 55.10 CNY per share, with a total market capitalization of 22.812 billion CNY [1] - Dabo Medical specializes in the production, research, and sales of high-value medical consumables, with its main business revenue composition being: trauma products 38.68%, spinal products 17.95%, minimally invasive surgical products 16.34%, joint products 10.37%, other products 9.27%, neurosurgical products 4.50%, and dental products 2.89% [1] Group 2 - Southern Fund's Southern CSI 1000 ETF (512100) is among the top ten circulating shareholders of Dabo Medical, having increased its holdings by 141,900 shares in the second quarter, totaling 756,800 shares, which represents 0.26% of the circulating shares [2] - The Southern CSI 1000 ETF has achieved a year-to-date return of 25.67% and a one-year return of 67.42%, ranking 1948 out of 4220 and 1298 out of 3814 respectively [2] Group 3 - The fund manager of Southern CSI 1000 ETF is Cui Lei, who has been in the position for 6 years and 323 days, with a total fund asset size of 94.976 billion CNY [3] - During Cui Lei's tenure, the best fund return was 139.52%, while the worst return was -15.93% [3]

Group 1 - The core viewpoint of the article highlights the recent performance and financial metrics of Dabo Medical (002901), indicating a slight increase in stock price and mixed capital flow on September 22, 2025 [1] - Dabo Medical's total market value is 22.345 billion yuan, ranking 11th in the medical device industry, with a net profit of 244 million yuan, which is significantly higher than the industry average [2] - The company reported a year-on-year revenue increase of 25.55% to 1.21 billion yuan in the first half of 2025, with a net profit increase of 76.69% [2] Group 2 - The stock has received one buy rating from an institution in the last 90 days, indicating positive sentiment among analysts [3] - The capital flow analysis shows that on September 22, 2025, there was a net outflow of 2.7 million yuan from main funds, while retail investors saw a net inflow of 7.17 million yuan [1][3] - The company's gross profit margin stands at 71.01%, significantly higher than the industry average of 51.85%, reflecting strong operational efficiency [2]

Core Viewpoint - The stock of Dabo Medical (002901) has shown a decline in price and a mixed flow of funds, indicating potential volatility in investor sentiment and market performance [1][2]. Group 1: Stock Performance - As of September 19, 2025, Dabo Medical's stock closed at 53.83 yuan, down 1.41% with a turnover rate of 0.71% and a trading volume of 20,600 shares, resulting in a transaction amount of 111 million yuan [1]. - Over the past five days, the stock has experienced fluctuations in price and fund flows, with a notable net outflow of 10.02 million yuan from main funds on September 19, 2025, which accounted for 8.99% of the total transaction amount [2]. Group 2: Fund Flow Analysis - The fund flow data for September 19, 2025, indicates that retail investors contributed a net inflow of 9.74 million yuan, representing 8.73% of the total transaction amount, while speculative funds saw a net inflow of 0.28 million yuan [1][2]. - The previous days showed a trend of net outflows from main funds, with the highest outflow recorded on September 17, 2025, at 19.66 million yuan, indicating a potential shift in investor confidence [2]. Group 3: Company Financials and Industry Position - Dabo Medical reported a total market capitalization of 22.287 billion yuan, with a net profit of 244 million yuan, reflecting a year-on-year increase of 76.69% [3]. - The company's gross margin stands at 71.01%, significantly higher than the industry average of 51.85%, positioning it favorably within the medical device sector [3]. - Dabo Medical's return on equity (ROE) is 7.6%, which is substantially above the industry average of 1.8%, indicating effective management and profitability [3].